Intra-Cellular Therapies, Inc. announced the presentation of a new network meta-analysis (NMA) demonstrating that CAPLYTA® (lumateperone) showed the greatest improvement across four key efficacy outcomes among FDA-approved adjunctive treatments for Major Depressive Disorder (MDD). The findings were featured in a late-breaking presentation at the 2026 NEI Spring Congress.
In the absence of head-to-head clinical trials, the NMA utilised indirect comparisons from placebo-controlled trials to evaluate the performance of atypical antipsychotics used alongside standard antidepressant therapy (ADT). CAPLYTA® achieved the highest ranking determined by Surface Under the Cumulative Ranking (SUCRA) curvesacross all four efficacy endpoints consisting of MADRS Total Score (reduction in depressive symptoms),MADRS Response, MADRS Remission and Clinical Global. Beyond symptom relief, the analysis highlighted a favorable safety profile that distinguishes CAPLYTA® from other adjunctive therapies. Notably, among the secondary endpoints evaluated, CAPLYTA® demonstrated no weight gain compared to placebo plus ADT. This is a critical finding for patients and clinicians, as metabolic side effects and weight gain are often cited as primary reasons for treatment discontinuation in MDD.
“The adjunctive treatments approved for MDD share a common indication but differ in their pharmacologic profiles, efficacy, and tolerability,” said Leonardo Diaz, M.D., Vice President, U.S. Medical Affairs, CAPLYTA®, Johnson & Johnson.“By ranking first in both efficacy and metabolic safety, CAPLYTA® offers a compelling option for the millions of adults who do not achieve an adequate response with standard antidepressants alone.”The NMA builds upon the robust results of Studies 501 and 502, reinforcing CAPLYTA’s® role as a leading therapy in the evolving MDD treatment landscape.
CAPLYTA® is an FDA-approved prescription medicine used in adults for the treatment of schizophrenia, depressive episodes associated with bipolar I or II disorder (as monotherapy or adjunctive therapy with lithium or valproate), and as an adjunctive treatment for MDD. As we look toward the future of mental health, these findings pave the way for a more personalised , “no-compromise” approach to treatment—enabling clinicians to move beyond simply managing symptoms to achieving sustained remission without the metabolic burdens that have historically hindered patient progress.
By Pragna Biswas
